Janssen Business Development

Identifying Pathways to Better Health
Through Collaboration

Learn more

About Us

Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.

Driving Collaborative Innovation to Accelerate Breakthroughs

If you are with an established pharmaceutical company, mid-sized to large biotechnology company, seek a collaboration or merger & acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.

Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, developments, and commercial partnerships.


  • Patrick Verheyen
    Global Head, Janssen Business Development
  • Sarah Brennan
    Sarah Brennan
    VP, Business Development, Cardiovascular & Metabolism
  • Marianne De Backer
    Marianne De Backer
    VP, Global M&A Operations and Divestitures (Pharmaceuticals Group), Global Infectious Diseases & Vaccines Business Development
  • Nicholas Franco
    Actelion Executive Vice President, Chief Business Development Officer
  • Johan L. J. Verbeeck
    VP, Business Development, Immunology
  • Lucinda Warren
    VP, Business Development, Neuroscience
  • Debi Watson
    VP, Business Development, Oncology


The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and larger biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s six defined therapeutic areas.

Strong Science Is at the Heart of Everything We Do

Our approach meaningfully integrates deal makers with science leaders from the very beginning. Having a clear and focused strategy that is grounded in the science allows the Janssen Business Development team to shape better deals and achieve in-market impact faster by understanding where each partner can add value.

Proven Two-Way Value Can Be Found in Every Partnership

The Janssen Business Development team has a proven, positive track record of deal performance. Our thoughtful approach to risk-taking includes spending the time to understand the needs of our partners so that deals can be structured to maximize value for all parties.

Dynamic Approaches Pave the Way to Success

Since no two deals are exactly alike, the Janssen Business Development team employs a flexible and adaptive approach to tailor the optimal deal structure to each unique partner opportunity. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving to optimize success.

True Collaboration Drives All of Our Actions

We are focused on genuine collaborations and seek out relationships with partners who desire transparency and openness, which we believe leads to new ideas and better solutions. Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship.

Focus Areas

Our Pharmaceuticals business is divided into six core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. We seek innovation across all of these areas where there is significant unmet patient need.

CLICK a circle below to see the diseases we are targeting.
  • Metabolism, Retinal Diseases, Thrombosis
    Cardiovascular and Metabolism
    Cardiovascular and Metabolism
  • Gastroenterology, Rheumatology - IL-23 Pathway
  • Hepatitis, Respiratory Infections, Bacterial & Viral Vaccines
    Diseases and Vaccines
    Infectious Diseases and Vaccines
  • Mood Disorders, Neurodegenerative Disorders, Schizophrenia, Glutamatergic Pathway Diseases
  • Prostate Cancer, Solid Tumor Targeted Therapy, Immuno-Oncology, Hematologic Malignancies
  • Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
    Pulmonary Hypertension
    Pulmonary Hypertension


  • Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

    United States
    Apr 16, 2018
  • Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer

    Lugano, Switzerland
    Mar 21, 2018
  • Janssen Enters into Worldwide Collaboration with Theravance Biopharma for oral, Pan-Jak Inhibitor Drug Candidate for the Treatment of Inflammatory Bowel Disease

    United States
    Feb 07, 2018


Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

Johan Verbeeck, DVM, MsC
Johnson & Johnson Innovation,
Janssen Business Development
Email: jverbee2@ITS.JNJ.com
Telephone: +1 609-730-4532



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.